痰热清注射液治疗加重期慢性阻塞性肺疾病临床研究

Clinical Study of Tanreqing Injection on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的:探讨痰热清注射液治疗加重期慢性阻塞性肺疾病(AECOPD)的临床疗效。方法:100例AECOPD随机平均分为对照组与观察组,各为50例。对照组给予盐酸氨溴索雾化吸入治疗,观察组在此基础上给予中药痰热清注射液治疗。比较两组临床疗效、治疗前后血气指标、肺功能、6分钟步行距离(6MWT)及不良反应发生情况等。结果:①对照组临床有效率为68.00%,显著低于观察组(96.00%)(P<0.01);②两组治疗前后血气指标(PaO2与PaCO2)及肺功能(FEV1与FEV1/FVC)差异,均具有统计学意义(P<0.05),且两组治疗后血气指标及肺功能差异也均具有统计学意(P<0.05);③对照组治疗前后6MWT分别为(301.25±54.32)m与(334.72±65.79)m,差异无统计学意义(P>0.05);观察组治疗前后6MWT分别为(302.66±59.71)m与(411.39±82.37)m,差异具有统计学意义(P<0.05),且两组治疗后6MWT差异也具有统计学意义(P<0.05);④两组治疗过程中未见任何不良反应发生。结论:痰热清治疗AECOPD效果显著,安全性高。

Objective：To investigate the efficacy of Tanreqing Injection in the treatment of acute exacerbation of chronic obstructive pul- monary disease（AECOPD）. Methods ：100 cases of acute exacerbation of chronic obstructive pulmonary disease were randomly divided into the control group and the observation group, each of 50 cases. The control group was given ambroxol hydrochloride aerosol inhalation therapy, and the observation group was treated with Tanreqing Injection on the basis of the control group. Clinical efficacy, blood gas a- nalysis before and after treatment, pulmonary function,6min walking test （6MWT） and the incidence of adverse reactions, etc. of the two groups were compared. Resuhs：（1）The effective rate of control group was 68.00% ,which was significantly lower than that of observation group （ 96.00% ） （ P 〈 0.01 ） ;（2）Comparison of blood gas analysis （ PaO2 and PaCO2 ） before and after treatment and pulmonary function （FEV1 and FEV1/FVC） of the two groups showed that the differences were statistically significant（ P 〈 0.05 ）, and after treatment ,differences of blood gas analysis and pulmonary function of the two groups were statistically significant （P 〈 0.05 ） ;（3）6MWT of the control group before and after treatment were respectively （301.25 ±54.32） m and （334.72 ±65.79） re,and the difference was not statistically significant （ P 〉 0. 05 ） ;6MWT of the observation group before and after treatment were respectively （ 302.66 ± 59.71 ） m and （411.39 ± 82.37 ） m, and the difference was statistically significance （ P 〈 0.05 ） , and the difference of 6MWT between the two groups after treatment also had statistically significant （ P 〈 0.05 ） ; （4）During treatment in both groups did not show any adverse reactions occur. Conclusion：Tanreqing Injection in the treatment of AECOPD has significant effect and high safety.